New IBD drug candidate SPH7854 begins first human safety tests

NCT ID NCT06483373

Recruiting now Knowledge-focused Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests the safety of a new drug called SPH7854 in 111 healthy adults. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The goal is to see if it is safe enough to test in people with inflammatory bowel disease in future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPH7854 granules
What this could lead to: If safe and well-tolerated, this could pave the way for testing SPH7854 as a potential treatment for inflammatory bowel disease.
What could go wrong: This is a very early Phase 1 trial in healthy people, not patients. It only checks safety and drug processing, not whether the drug works for IBD. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASE

Contacts and locations

Locations

West China Second University Hospital, Sichuan University
RECRUITING

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.